- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02800967
The Effects of Aronia Juice Polyphenols on Cardiovascular Disease Risk (AMARCord)
Investigation of Beneficial Effects of Aronia Juice (Aronia Melanocarpa) and Dietary Polyphenols on the Activity of Thrombocytes as Well as Other Risk Factors Causing Cardio-vascular Diseases
Study Overview
Status
Conditions
Detailed Description
To investigate the effect of Aronia (Aronia melanocarpa L.) juice polyphenols on platelet function and other CVD risk factors a three-arm, crossover design, randomized, double-blind placebo-controlled clinical trial will be performed in apparently healthy subjects at moderate CVD risk.
Recruited participants will be randomly assigned to one of three interventions (pure Aronia juice, Aronia beverage or placebo beverage) in the first phase and followed by cross-over in second and third phase. Two-week run-in period with low intake of polyphenols will precede the start of the intervention, ie. the first intervention phase. During each of three intervention periods (phases) subjects will consume 100 ml of each intervention product daily for 28 days, with 28 days of wash out period between different phases.
Blood and urine samples will be taken at baseline, before and after 28 days after each intervention period. Platelet analyses by flow cytometry, biochemical analyses of plasma samples, full blood count, blood pressure and anthropometric measurements will be performed at each study visit.
During the first study visit, regardless the allocation, blood samples will be taken before and 2h after the consumption of first 100 ml of intervention product (performed at the experimental site) and the analysis of markers of platelet function, biochemical parameters (glucose, triglycerides, and uric acid) and blood pressure will be assessed.
Subjects will be instructed to avoid rich-sources of anthocyanins and procyanidins during the whole study. Dietary habits will be assessed by food frequency questionnaire (FFQ) performed 2 times at the beginning and at the end of the study and 24h-recall performed at the beginning and after each wash out period.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Belgrade, Serbia, 11000
- Centre of Research Excellence in Nutrition and Metabolism, Institute for Medical Research, University of Belgrade
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- BMI: 25-30 or
- Central obesity ie. WC≥80 cm (women) and ≥94 cm (man) or
- Normal (systolic blood pressure (SBP): 120-129; diastolic blood pressure(DBP): 80-84) or high normal (SBP:130-139; DBP:85-89) blood pressure
Exclusion Criteria:
- Smokers
- Diagnosed with CVD, history of stroke or CVD
- Diagnosis of type 2 diabetes mellitus on insulin therapy
- Very low or high blood pressure (<90/50)
- Pregnant or have been pregnant in the last 12 months or on oral contraceptives
- Gastrointestinal diseases
- Diagnosed with a long-term illness requiring active treatment, e.g. cancer, thyroid, adrenal, pituitary diseases
- On regularly prescribed medication known to have a profound effect on CVD risk factors (including statins)
- Non-steroidal anti-inflammatory drugs including creams
- Sufferers of asthma and/or hay-fever
- Known allergy to any of investigated polyphenol-rich food
- Regularly using antacids and laxatives (at least once a week)
- Unwillingness to discontinue specific dietary (other than vitamins and minerals) or herbal supplements less than one month prior to the start of the study and for the duration of the study
- Unwillingness to restrict oily fish consumption to 2 portions or less per week less than one month prior to the start of the study and for the duration of the study
- Taking paracetamol for more than one day during the intervention period and unwillingness to continue with the study intervention for an additional 48 hours if paracetamol is taken
- Blood donation within 16 weeks of the first study sample and who intend to donate blood less than 16 weeks after the last study sample
- Those who receive or plan to receive any type of immunization during the study period and those who have received an immunization within 4 weeks of the start of the study
- Parallel participation in another research project which involves dietary intervention (e.g. taking vitamin supplements) or sampling of blood that may increase the total volume taken above 470 mL in a 4 month period
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Pure Aronia juice
Participants will consume 100 ml of pure Aronia juice per day for 28 days
|
Pure Aronia juice with appx.
polyphenols content of 1000 mg gallic acid equivalents/100ml
|
Active Comparator: Aronia juice-based beverage
Participants will consume 100 ml of Aronia juice-based beverage per day for 28 days.
|
Aronia juice-based beverage with appx.
polyphenols content of 250 mg gallic acid equivalents/100ml, obtained as a blend of ¼ vol. of pure Aronia juice and ¾ vol. of placebo beverage.
|
Placebo Comparator: Placebo beverage
Participants will consume 100 ml of Placebo beverage per day for 28 days
|
A polyphenol-free formulation with matched nutrient composition (sugars, vitamins, minerals) and similar sensory characteristics to active interventions
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in the percentage of P-selectin and glycoprotein IIbIIIa (GPIIbIIIa) positive platelets, percentage of platelet-monocyte and platelet-neutrophil aggregates, between baseline and endpoint within the intervention group vs. control group.
Time Frame: Baseline, 2 hours and 4 weeks
|
Percentage of P-selectin and GPIIbIIIa positive platelets evaluated in total number of 20000 platelets, percentage of platelet-monocyte aggregates in 1000 monocytes and percentage of platelet-neutrophil aggregates in total 20000 neutrophils, all by flow cytometry, in non-treated blood samples and after ex vivo treatment of the whole blood with adenosine-diphosphate (0.5 μM and 20 μM)
|
Baseline, 2 hours and 4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in serum glucose levels between baseline and endpoint within the intervention group vs. control group.
Time Frame: Baseline, 2 hours and 4 weeks
|
In 12h-fasting and 2h postprandial serum samples analysed by biochemical analyser.
|
Baseline, 2 hours and 4 weeks
|
Changes in serum cholesterol levels between baseline and endpoint within the intervention group vs. control group.
Time Frame: Baseline and 4 weeks
|
Total cholesterol, LDL-cholesterol and HDL-cholesterol levels in 12h-fasting serum samples analysed by biochemical analyser
|
Baseline and 4 weeks
|
Changes in serum triglycerides levels between baseline and endpoint within the intervention group vs. control group.
Time Frame: Baseline, 2 hours and 4 weeks
|
In 12h-fasting and 2h postprandial serum samples analysed by biochemical analyser
|
Baseline, 2 hours and 4 weeks
|
Changes in systolic and diastolic blood pressures between baseline and endpoint within the intervention group vs. control group.
Time Frame: Baseline, 2 hours and 4 weeks
|
Mean of 3 x 2 consecutive office measurements performed within 30 min at each time point with professional OMRON device
|
Baseline, 2 hours and 4 weeks
|
Changes in body weight between baseline and 4 weeks within the intervention group vs. control group.
Time Frame: Baseline and 4 weeks
|
Body weight will be measured by bio-impedance scale
|
Baseline and 4 weeks
|
Changes in waist circumference between baseline and 4 weeks within the intervention group vs. control group.
Time Frame: Baseline and 4 weeks
|
Waist circumference will be measured by professional tape, according to the guidelines
|
Baseline and 4 weeks
|
Changes in body mass index between baseline and 4 weeks within the intervention group vs. control group.
Time Frame: Baseline and 4 weeks
|
Body mass index will be calculated based on values obtained as body weight in kilograms divided by height in meters squared.
|
Baseline and 4 weeks
|
Changes in the percentage of body fat between baseline and 4 weeks within the intervention group vs. control group
Time Frame: Baseline and 4 weeks
|
Body fat as percentage of total weight measured by bio-impedance instrument
|
Baseline and 4 weeks
|
Changes in the percentage of body water between baseline and 4 weeks within the intervention group vs. control group
Time Frame: Baseline and 4 weeks
|
Body water as percentage of total weight measured by bio-impedance instrument
|
Baseline and 4 weeks
|
Changes in total body muscle mass between baseline and 4 weeks within the intervention group vs. control group
Time Frame: Baseline and 4 weeks
|
Percentages of total body muscle mass in kilograms will be measured by bio-impedance instrument
|
Baseline and 4 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in parameters of liver function between baseline and endpoint
Time Frame: Baseline and 4 weeks
|
Aspartate transferase, alanine transferase , direct bilirubin, total bilirubin, gamma-glutamyl transferase , lactate dehydrogenase levels in 12h-fasting serum samples analysed by biochemical analyser
|
Baseline and 4 weeks
|
Changes in parameters of renal function between baseline and endpoint
Time Frame: Baseline and 4 weeks
|
Urea and creatinine levels in 12h-fasting serum samples analysed by biochemical analyser
|
Baseline and 4 weeks
|
Changes in uric acid, iron and oxLDL level between baseline and endpoint within the intervention group vs. control group.
Time Frame: Baseline and 4 weeks
|
In 12h-fasting serum samples analysed by biochemical analyser
|
Baseline and 4 weeks
|
Changes in full blood count between baseline and endpoint
Time Frame: Baseline and 4 weeks
|
Baseline and 4 weeks
|
|
Changes in total caloric intake and intake of total polyphenols
Time Frame: Baseline and 4 weeks
|
Both caloric intake and intake of polyphenols will be assessed by standardized food-frequency questionnaire and 24-recall at baseline and after each wash-out period, based on data from Serbian Food Composition database.
The agreements between two methods will also be assessed.
|
Baseline and 4 weeks
|
Changes in urine levels of major polyphenol metabolites between baseline and endpoint
Time Frame: Baseline, 2h and 4 weeks
|
Measured in spot urine of total morning void by liquid chromatography
|
Baseline, 2h and 4 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Maria Glibetic, University of Belgrade
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Bacchus_AMARCord_2013
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
BayerCompletedPrimary HypertensionChina
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Addpharma Inc.Recruiting
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
-
China Academy of Chinese Medical SciencesGuang'anmen Hospital of China Academy of Chinese Medical SciencesCompletedHypertension, Resistant to Conventional Therapy | Primary HypertensionChina
-
Sulaiman AlRajhi CollegesUnknownHypertension, Essential | β-hydroxybutyrate
Clinical Trials on Pure Aronia juice
-
University of North DakotaUSDA Grand Forks Human Nutrition Research Center; Altru Health SystemCompletedInflammation | Oxidative Stress | Mental Health Wellness 1United States
-
Medical University of GrazRecruitingDepression | Obesity | Microbial Colonization | Diet, Healthy | Immune System ToleranceAustria
-
Montana State UniversityCompletedInflammation | Hypertriglyceridemia | Metabolic DisorderUnited States
-
Montana State UniversityCompletedInflammation | Obesity | Metabolic Syndrome | HypertriglyceridemiaUnited States
-
University of AarhusActive, not recruiting
-
Odense University HospitalCompleted
-
University of AarhusCompletedBioavailabilityDenmark
-
TCI Co., Ltd.CompletedSkin Condition | Anti Oxidative StressTaiwan
-
Maastricht University Medical CenterBioActor B.V.Completed
-
City, University of LondonBarts & The London NHS TrustRecruitingVitamin D Status | Hyperglycemia, PostprandialUnited Kingdom